Home \ General \ Mexidol®. Evidence-based medicine: making the complex simple.

Mexidol®. Evidence medicine: just about the complex.

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:
  • 00:00

    Evidence medicine and randomized clinical trials.

  • 04:09

    Levels of evidence -based medicine. The reliability of the evidence and the persuasiveness of the recommendations. Clinical recommendations.

  • 12:50

    Sample of the studied patients and the results of clinical research

  • 15:35

    Antioxidant and antihypoxic effects of the drug

  • 17:35

    Mexidol® is the most studied drug in the group of ethylmethylhydroxypyridine of succinate

  • 18:42

    RCI Epica - primary and final points in the study. The results of the study of the drug Mexidol® in patients with acute cerebral stroke

  • 26:00

    RCT memo - effectiveness and safety of the drug Mexidol® in the treatment of chronic brain ischemia. Sample, research design and results.

  • 33:13

    RCTs Mega - Mexidol® children: the effectiveness and safety of the drug in the treatment of a deficiency of attention and hyperactivity deficiency in children from 6 years old. Sample, research design and results.

Evgeniya Viktorovna Yekusheva – Doctor of Medical Sciences, Professor, Head of the Department of Nervous System Diseases and Neurorehabilitation of the Academy of Postgraduate Education of the Federal Scientific and Clinical Center of the Federal Medical and Biological Agency of Russia

Ivan Aleksandrovich Shchukin – PhD, Associate Professor of the Department of Neurology, Neurosurgery and Medical Genetics of the Leningrad Branch of the N.I. Pirogov Russian National Research Medical University

Announcement:

Evidence-based medicine is a principle of clinical practice based on the results of randomized controlled trials, rather than the individual opinions and views of a particular physician. A randomized controlled trial is a method of scientific and practical medical experimentation in which subjects are randomly divided into groups: some patients are assigned to the experimental – main – group (e.g., treatment group), while others are assigned to the control group (e.g., placebo group). Clinical guidelines based on the evidence base and the results of numerous studies have been and continue to be developed. They help determine which drug or treatment method is effective in each specific case. One drug that meets the requirements of evidence-based medicine and is also included in clinical guidelines for the treatment of stroke is Mexidol®.Important effects of the drug include antioxidant, antihypoxant, and membrane-stabilizing properties.

All videos Next video

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:
  • 00:00

    Evidence medicine and randomized clinical trials.

  • 04:09

    Levels of evidence -based medicine. The reliability of the evidence and the persuasiveness of the recommendations. Clinical recommendations.

  • 12:50

    Sample of the studied patients and the results of clinical research

  • 15:35

    Antioxidant and antihypoxic effects of the drug

  • 17:35

    Mexidol® is the most studied drug in the group of ethylmethylhydroxypyridine of succinate

  • 18:42

    RCI Epica - primary and final points in the study. The results of the study of the drug Mexidol® in patients with acute cerebral stroke

  • 26:00

    RCT memo - effectiveness and safety of the drug Mexidol® in the treatment of chronic brain ischemia. Sample, research design and results.

  • 33:13

    RCTs Mega - Mexidol® children: the effectiveness and safety of the drug in the treatment of a deficiency of attention and hyperactivity deficiency in children from 6 years old. Sample, research design and results.

Block of articles on this topic

The results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of consistent therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)

Registered on ClinicalTrials 

A.I. FEDIN1, V.V. ZAKHAROV2, M.M. TANASHYAN3, E.I. CHUKANOVA1, E.N. MAJIDOVA4, L.A. SCHEPANKEVICH5.6, O.D. OSTROUMOVA7

1Pirogov Russian National Research Medical University, Moscow, Russia;
2I.M. Sechenov First Moscow Medical University,
3Neurology Research Center,
4, Russia;
5Novosibirsk State Medical University, Novosibirsk
6Federal Research Center for Fundamental and Translational Medicine, Novosibirsk, Russia;
7Russian Medical Academy of Continuous Professional Education, Moscow, Russia

 

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2021, Vol. 121, No. 11

Read more
The results of a randomized double blind multicenter placebo-controlled in parallel groups of the study and safety of Mexidol with prolonged consistent therapy in patients in acute and early restorations. Periods

Authors:
L.V. STAKHOVSKAYA1, N.A. SHAMALOV1, D.R. KHASANOVA2, E.V. MELNIKOVA3, A.S. AGAFINA4, K.V. GOLIKOV5, E.I. BOGDANOV6, A.A. YAKUPOVA6, L.V. ROSHKOVSKA7, L.V. LUKINYKH8, T.M. LOKSHTANOVA9, I.E. Poverennova10, L.A. SCHEPANKEVICH11

1Research Institute of Cerebrovascular Pathology and Stroke, Pirogov Russian National Research Medical University, Moscow, Russia;
2Interregional Clinical and Diagnostic Center, Kazan, Russia;
3St. Petersburg City Hospital No. 26, St. Petersburg, Russia;
4St. Petersburg City Hospital No. 40 of the Kurortny Administrative District, St. Petersburg, Russia;
5St. Petersburg City Multidisciplinary Hospital No. 2, St. Petersburg, Russia;
6Kazan State Medical University, Kazan, Russia;
7St. Petersburg Nikolaevskaya Hospital, St. Petersburg, Russia;
8Vsevolozhsk Clinical Interdistrict Hospital, Leningrad Region, Russia.
9MUBZ City Clinical Hospital No. 1 named after N.I. Pirogov, Samara, Russia;
10State Budgetary Healthcare Institution Samara Regional Clinical Hospital named after V.D. Seredavin, Samara, Russia;
11Federal State Budgetary Scientific Institution Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russia.

Read more
The results of a multicenter dual blind randomized placebo-controlled clinical study on the assessment of the effectiveness and safety of the drug Mexidol in the treatment of attention deficit syndrome in children (mega)

Registered on ClinicalTrials 

 

N.N. ZAVADENKO1, N.Yu. SUVORINOVA1, T.T. BATYSHEVA2, O.V. BYKOVA2, A.N. PLATONOVA2, D.D. GAYNETDINOVA3, E.V. LEVITINA4, V.V. MASHIN5, I.N. VAKULA6, N.E. MAKSIMOVA7

1Pirogov Russian National Research Medical University, Moscow, Russia;
2Scientific and Practical Center for Child Psychoneurology, Moscow Department of Health, Moscow, Russia;
3Kazan State Medical University, Kazan, Russia;
4Tyumen State Medical University, Tyumen, Russia;
5Ulyanovsk State University, Ulyanovsk, Russia;
6Center for Professional Therapy, Krasnodar, Russia.

7FSBEI in the Tver State Medical University, Tver, Russia

 

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2022, Vol. 122, No. 4

Read more
Randomized dual-blind, placebo-controlled study of the effectiveness and safety of Mexidol in the complex therapy of ischemic stroke in the acute period

Author:
V. I. SKBORTSOVA, L. V. STAKHOVSKAYA, Y. R. NARCISSOV, M. K. BODYKHOV, I. ​​V. KICHUK, Y. V. GUDKOVA, T. A. SOLDATENKOVA, T. T. KONDRASHOVA, E. V. KALININA, M. A. NOVICHKOVA, O. B. KERBIKOV

Department of Fundamental and Clinical Neurology of the Russian State Medical University, Research Institute of Cytochemistry and Molecular Pharmacology, Moscow

Read more
Original and reproduced drugs: what do the clinician need to know?

Author:
A.V. SHCHULKIN, A.A. FILIMONOVA
Federal State Budgetary Educational Institution of Higher Education “Ryazan State Medical University” of the Ministry of Health of the Russian Federation, Ryazan, Russia

Read more

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com